Patients with acute myeloid leukaemia are often unable to tolerate intensive chemotherapy, and the outcomes of these patients have improved considerably following the availability of regimens containing the BH3 mimetic venetoclax. Nonetheless, not all of these patients will respond to venetoclax, and virtually all will ultimately develop resistance, indicating a need for novel treatment strategies targeting this pathway. In this Review, the authors describe the development of BCL-2 inhibitors, discuss mechanisms of resistance and summarize ongoing research efforts aimed at optimizing the therapeutic benefit of these agents.
- Antonino Glaviano
- Ellen Weisberg
- Alan P. Kumar